World pharmaceutical sales by region Premium Industry-specific and extensively researched technical data partially from exclusive partnerships. A paid subscription is required for full access. Global pharmaceutical sales from toby region in billion U. As of Q3total pharmaceutical sales in the United States was estimated to reach around billion U.
UAE 23 October, Dubai: This level of focus on the emergence of the UAE as a major pharmaceutical manufacturer and exporter is not a new one, but it has been gaining momentum recently. June saw another strategic framework announced by His Highness Sheikh Mohammed bin Rashid Al Maktoum with the launch of Dubai Industrial Strategyfurther driving Dubai to become a global platform for knowledge-based, sustainable and innovation-focused businesses.
Among the six priority sectors identified in the strategy are Emerging pharmaceutical markets in turkey q3 and medical equipment, due to their importance to Dubai Plan and future growth potential. The term innovation is often associated with Research and Development and the launch of new medications.
However, innovation also encompasses finding improved methods of delivering existing treatments. For example, replacing an injectable with an oral dose, or substituting an oral tablet with a patch. By offering patients alternative routes to administration, we can improve the patient experience and increase the likelihood of patients remaining compliant with their recommended courses of treatment.
As the patents expire on medications, manufacturers, such as Pharmax, have the opportunity to mass-produce generic alternatives. Generic medications are more affordable than name-branded alternatives, making them a more attractive alternative for insurance providers and sufferers of chronic illnesses where long-term treatment is indicated.
In addition to generic forms of medications, complex generic forms are a focus for both the region and Pharmax. Complex generic medications provide higher margins when compared to generics, further incentivising local manufacturers to seek out innovation in the delivery of treatments.
A key milestone was the requirement of mandatory health insurance for all residents. Access to universal healthcare has increased demand for affordable medications used in the treatment of chronic illnesses. Historically, the UAE has relied upon the importation of medicines from the international market.
However, with government support for local manufacturers, including Pharmax Pharmaceuticals, local companies have a unique opportunity to produce locally-manufactured medications and treatments and enter the market. Private sector pharmaceutical manufacturing companies are also being encouraged to seek out and create partnerships at every level of the sector.
In addition to equipping its new state-of-the-art facility with European-sourced equipment, Pharmax is entering into technology agreements with world-class pharmaceutical companies with a view to offer patients in the UAE and GCC medications with improved delivery systems.
When Pharmax was in the very early stages of its establishment, we considered only one location for our headquarters — Dubai. When looking at the requirements for launching and running a successful pharmaceutical manufacturing business, Dubai Science Park DSP was a perfect fit.
InDSP and its taskforce partners identified five prime areas for innovation in the local healthcare sector, including complex generics. In adherence with the efforts of the UAE Government to transform the United Arab Emirates into one of the most innovative countries in the world, the UAE is taking great strides towards becoming a leading global healthcare destination, offering best practices in patient care and locally-produced medication.
Pharmax Pharmaceuticals provides access to affordable, branded generic medication. Committed to exceeding the expectations of healthcare providers, practitioners and patients, Pharmax offers a diverse range of medications across a wide range of therapeutic areas.
Headquartered in Dubai, UAE, Pharmax is a GMP-licensed international manufacturer and distributor of high-quality medications into most regulated markets globally. Pharmax is committed to maintaining a culture of quality and its state-of-the-art facility meets stringent local and global regulatory standards.
The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content.
Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release. The press release is provided for informational purposes only.The Gross Domestic Product (GDP) in Turkey expanded percent in the second quarter of over the previous quarter.
GDP Growth Rate in Turkey averaged percent from until , reaching an all time high of percent in the first quarter of and a record low of percent in the second quarter of Turkey is classified as an emerging market economy.
Read More: Angola Pharmaceuticals & Healthcare Report BMI View: The Angolan pharmaceuticals and healthcare market will continue to perpetuate a high-risk environment for multinational drugmakers, with limited commercial rewards for those firms producing patented medicines.
The company said worldwide pharmaceutical sales rose % to $ billion, offsetting a % decline in medical device sales, which came in at $ billion.
Global consumer sales rose % to $3. Researcher’s View: Sourcing accurate and reliable quantitative data on Tanzania’s pharmaceutical market remains challenging due to substandard audits, porous sales channels, a high prevalence of counterfeits, questionable national statistics, dispensing without prescriptions, sizeable ‘grey markets’ and the widespread use of traditional .
Emerging markets involve heightened risks related to the same factors as well as increased volatility, lower trading volume, and less liquidity. Emerging markets can have greater custodial and operational risks, and less developed legal and accounting systems than developed markets.
The Harding Loevner Emerging Markets Portfolio (Advisor Class) returned % during the third quarter of , compared with the % return for its benchmark, the MSCI Emerging Markets Index.